The Effects of Upper Extremity Aerobic Exercise Training in Patients With Type 2 Diabetes

Sponsor
Gazi University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06132334
Collaborator
(none)
40
1
2
25
1.6

Study Details

Study Description

Brief Summary

Type 2 diabetes (T2DM) is a metabolic disease characterized by chronic hyperglycemia that occurs as a result of any disorder in insulin secretion or insulin activity. Regular physical activity is important in preventing and managing this disease.

Condition or Disease Intervention/Treatment Phase
  • Other: Upper extremity aerobic exercise training
  • Other: Control Group
N/A

Detailed Description

T2DM causes significant mortality and morbidity, increases healthcare costs, and increases the risk of cardiovascular disease. Due to the rapid increase in the number of individuals with diabetes, preventing and controlling this disease and living with diabetes is important. In patients with T2DM, pulmonary functions decrease in relation to glycemic control and disease duration. Decrease in cardiorespiratory fitness can lead to cardiovascular mortality. Cardiovascular mortality increases as exercise capacity decreases. Although the determinants of exercise intolerance in diabetes are not fully understood, a number of abnormalities in pulmonary diffusion capacity, maximum cardiac output, blood oxygen capacity and skeletal muscle properties cause exercise tolerance. Peripheral factors such as skeletal muscles also affect exercise intolerance. Insufficient oxygen use in skeletal muscles is considered one of the causes of exercise intolerance in T2DM patients. To reduce the cardiovascular mortality rate and risk factors associated with cardiovascular disease, physical activity level is important in T2DM patients, as in all populations. Maintaining physical activity level plays a protective role against both T2DM and cardiovascular disease. But traditional exercise training guides generally focus on walking exercises. Because exercises in this form are frequently used in daily life activities. It is known that upper extremity movements are frequently used in daily living activities, and aerobic exercise using the upper extremities is thought to be safe and effective in these patients due to diabetic foot complications. There is no study in the literature investigating the effects of upper extremity aerobic exercise training in T2DM.

The primary aim of the study is to investigate the effects of upper extremity aerobic exercise training applied to T2DM patients on exercise capacity, muscle oxygenation and physical activity level.

The secondary aim of the study is to investigate its effects on upper extremity functional exercise capacity, dual task performance, respiratory functions, respiratory muscle strength and endurance, peripheral muscle strength, shortness of breath, fatigue, depression, anxiety, sleep and quality of life.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Parallel AssignmentParallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
Triple-blind study; the patients will not be informed about training group or control group and they will be evaluated and trained at different places and times.
Primary Purpose:
Treatment
Official Title:
The Effects of Upper Extremity Aerobic Exercise Training on Exercise Capacity, Muscle Oxygen, and Physical Activity Level in Patients With Type 2 Diabetes
Anticipated Study Start Date :
Dec 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2025
Anticipated Study Completion Date :
Dec 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Upper extremity aerobic exercise training

The training group will receive upper extremity aerobic exercise training on an arm ergometer accompanied by a physiotherapist for 6 weeks.

Other: Upper extremity aerobic exercise training
Aerobic exercise training will be given to the training group on an arm ergometer 3 days in a week and 30-45 minutes a day for 6 weeks with the assistance of a physiotherapist. The training workload of aerobic exercise training will be applied at 50-80% of peak oxygen consumption or 60-80% of peak heart rate, dyspnea 3-4 points according to the Modified Borg Scale (MBS) or fatigue 4-6 points. Blood sugar measurement will be performed before exercise training. Individuals with a blood sugar result of >300 mg/dL will not be allowed to exercise that day.

Sham Comparator: Control Group

The control group will not be given any training for 6 weeks during the study period.

Other: Control Group
The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.

Outcome Measures

Primary Outcome Measures

  1. Oxygen consumption [through study completion, an average of 2 year]

    Maximum exercise capacity will be assessed by symptom-limited cardiopulmonary exercise testing on a treadmill at gradually increasing speed and degree, and oxygen consumption will be measured during the test.

  2. Muscle oxygenation [through study completion, an average of 2 year]

    Before the cardiopulmonary exercise test and the 6-minute pegboard and ring test (6-PBRT), during and after the tests the muscle oxygenation will be measured by using a near-infrared spectroscopy device.

  3. Physical activity level [through study completion, an average of 2 year]

    A multi-sensor activity monitor will be used to assess the level of physical activity

Secondary Outcome Measures

  1. Upper extremity functional exercise capacity [through study completion, an average of 2 year]

    It will be evaluated with a 6-minute pegboard and ring test. At the end of six minutes, the total number of rings inserted will be recorded in numbers.

  2. Pulmonary function (Forced vital capacity (FVC)) [through study completion, an average of 2 year]

    Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria. With the device, forced vital capacity (FVC) will be evaluated.

  3. Pulmonary function (Forced expiratory volume in the first second (FEV1)) [through study completion, an average of 2 year]

    Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to ATS and ERS criteria. With the device, forced expiratory volume in the first second (FEV1) will be evaluated.

  4. Pulmonary function (FEV1 / FVC) [through study completion, an average of 2 year]

    Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to ATS and ERS criteria. With the device, FEV1 / FVC will be evaluated.

  5. Pulmonary function (Flow rate 25-75% of forced expiratory volume (FEF 25-75%)) [through study completion, an average of 2 year]

    Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to ATS and ERS criteria. With the device, flow rate 25-75% of forced expiratory volume (FEF 25-75%) will be evaluated.

  6. Pulmonary function (Peak flow rate (PEF)) [through study completion, an average of 2 year]

    Pulmonary function will be evaluated with the spirometry. Dynamic lung volume measurements will be made according to ATS and ERS criteria. With the device, peak flow rate (PEF) will be evaluated.

  7. Dual task performance [through study completion, an average of 2 year]

    The test consists of 3 parts. Cognitive task, motor task and dual task will be evaluated. Patients will perform the Timed up and go (TUG) task as a single motor task. For the dual task, participants will be asked to perform the TUG test while counting down in increments of 3, starting from 100.As a single cognitive task, the individual will be asked to count down the specified number in increments of 3, while sitting comfortably in a quiet room, for the duration of the single task TUG. The total number of answers and the number of correct answers will be used to calculate the correct response rate as an indicator of cognitive performance during the dual task.

  8. Respiratory Muscle Strength [through study completion, an average of 2 year]

    Maximal inspiratory (MIP) and maximal expiratory (MEP) pressures expressing respiratory muscle strength were measured using a portable mouth pressure measuring device according to American Thoracic Society and European Respiratory Society criteria

  9. Respiratory Muscle Endurance [through study completion, an average of 2 year]

    Respiratory muscle endurance will be assessed by the POWERbreathe Wellness (POWERbreathe, Inspiratory Muscle Training (IMT) Technologies Ltd., Birmingham, UK) device and the respiratory muscle endurance test at increased threshold load.

  10. Peripheral muscle strength (N) [through study completion, an average of 2 year]

    Shoulder flexion muscles and Quadriceps femoris muscle strength will be measured by using a hand-held dynamometer. This values is expressed in Newtons (N).

  11. Dyspnea in daily life [through study completion, an average of 2 year]

    "Modified Medical Research Council" dyspnea scale will be used to question dyspnea perception during activities. This scale is a 5-point scale based on rating various physical activities that increase shortness of breath. The lowest and highest values on this scale are as follows: Level 0 "No shortness of breath except strenuous exercise" and level 4 "Too breathless to leave the house or breathless while dressing or undressing."

  12. Fatigue [through study completion, an average of 2 year]

    Fatigue will be assessed with Fatigue Severity Scale (Turkish version). This scale includes 9 items and each item scores from 1 (strong disagreement) to 7 (strong agreement) point. Fatigue Severity Scale total score is calculates by deriving an arithmetic mean. Cut-score of over 4 means significant fatigue and higher score indicates more severe fatigue.

  13. Anxiety and Depression [through study completion, an average of 2 year]

    The Turkish version of the Hospital Anxiety and Depression Scale (HADS) will be used. HADS score ranges from 0-42. A high score indicates increased levels of anxiety and depression.

  14. Sleep Quality [through study completion, an average of 2 year]

    It will be evaluated with the Turkish version of the Epworth Sleepiness Scale (EDS). The scale is designed to evaluate the sleepiness level of individuals during the day and is widely used. Total score is between 0-24. The range specified for normal sleep tendency is considered to be 0-10 points. Sleep is disrupted with a score of 11 points or above.

  15. Life quality [through study completion, an average of 2 year]

    Quality of life will be evaluated with the Turkish adaptation of the Diabetes Quality of Life Scale (DQOL). The scale is calculated out of 0-100 points. High scores indicate good quality of life.

  16. Diabetes symptoms [through study completion, an average of 2 year]

    It will be evaluated with the Diabetes Symptoms Checklist Scale ((DSC-R).The total score and all subscale scores on the scale range from 0 to 5, with higher scores indicating greater symptom burden.

  17. Dyspnea perception [through study completion, an average of 2 year]

    Modified Borg Scale: The Modified Borg scale is a subjective scale that scores 0-10 for breathlessness and fatigue at rest and/or during activity. The lowest 0 points "not at all" the highest 10 points "very severe" means shortness of breath.

  18. Peripheral muscle strength (%) [through study completion, an average of 2 year]

    Shoulder flexion muscles and Quadriceps femoris muscle strength will be measured by using a hand-held dynamometer. This values is expressed as a percentage (%) of the expected value.

  19. Upper extremity functional exercise capacity (percentage of the expected value (%)) [through study completion, an average of 2 year]

    It will be evaluated with a 6-minute pegboard and ring test.The total number of rings each participant is expected to wear will be calculated. The percentage of the number of rings made relative to the expected value will be expressed as a percentage of the expected value (%).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosed with T2DM,

  • Aged between 18-65 years,

  • Able to walk and cooperate,

  • Patients who volunteer to participate in the study.

Exclusion Criteria:
  • Body mass index >40 kg/m2,

  • A known lung disease,

  • Serious neurological, neuromuscular, orthopedic, or other diseases affecting physical functions,

  • Cognitive impairment that causes them to have difficulty understanding and following exercise test instructions,

  • Having had any cardiac event or surgery in the last six months,

  • Participated in a planned exercise program within the last three months,

  • Uncontrolled hypertension,

  • An acute pulmonary exacerbation within the last 4 weeks, have an acute upper or lower respiratory tract infection,

  • Presence of diabetes complications such as nephropathy, retinopathy and severe neuropathy,

  • Contraindications for exercise testing and/or exercise training according to the American College of Sports Medicine.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Cardiopulmonary Rehabilitation Clinic Çankaya Ankara Turkey 06560

Sponsors and Collaborators

  • Gazi University

Investigators

  • Study Chair: Fidan YILMAZ, MSc, Gazi University
  • Principal Investigator: Ayşenur SARISAKALOĞLU, MSc, Gazi University
  • Principal Investigator: Serpil GÜLKAN, MD, Pursaklar State Hospital
  • Study Director: Meral BOŞNAK GÜÇLÜ, Prof. Dr., Gazi University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Meral Boşnak Güçlü, Study director, PT, PhD, Prof.Dr. Faculty of Health Sciences, Department of Cardiopulmonary Physiotherapy and Rehabilitation, Gazi University
ClinicalTrials.gov Identifier:
NCT06132334
Other Study ID Numbers:
  • Gazi University63
First Posted:
Nov 15, 2023
Last Update Posted:
Nov 15, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Meral Boşnak Güçlü, Study director, PT, PhD, Prof.Dr. Faculty of Health Sciences, Department of Cardiopulmonary Physiotherapy and Rehabilitation, Gazi University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 15, 2023